← Back to all trials
Completed
NCT04285918
Evaluation of Prevalence and Clinical Impact of Atrial Fibrillation in Elderly Patients With Cryptogenic Stroke and High-Risk Patent Foramen Ovale
Conditions: Cryptogenic Stroke, Patent Foramen Ovale
Sex: All
Ages: 60 Years – N/A
Healthy volunteers: No
Enrollment: 184
Sponsor: Asan Medical Center
Location: Asan Medical Center Seoul
Summary
The purpose of DEFENSE-ELDERLY is to identify the prevalence of AF and evaluate the clinical impact of AF in elderly ESUS patients and no other known sources of stroke besides a high-risk patent foramen ovale, and compare it with elderly ESUS patients without high-risk PFO (no PFO or non-high risk PFOs)
Eligibility Criteria
Inclusion Criteria:
* Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature) (cohort A)
* Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO (cohort B)
* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the institutional review board
* Patients who are scheduled to have implantable cardiac monitoring
Exclusion Criteria:
* Transient ischemic attack
* Lacunar infarction (infarction at subcortical area with a lesion diameter less than 2cm on MR)
* Presence of complex aortic atheroma (≥4mm in plaque thickness or presence of mobile components)
* Presence of ≥50% luminal stenosis (extra- or intracranial) in arteries supplying the ischemic area
* Unwillingness or inability to comply with the procedures described in this protocol
* Life expectancy \< 1 years for any non-cardiac or cardiac causes
* High-risk anatomical feature of PFO; 1 of the 4 criteria described below PFO with an atrial septal aneurysm (protrusion of the dilated segment of the septum at least 15 mm beyond the level surface of the atrial septum), hypermobility (phasic septal excursion into either atrium ≥10mm), or PFO size (maximum separation of the septum primum from the secundum during the Valsalva maneuver \>2 mm), appearance of more than 30 microbubbles in the left atrium within three cardiac cycles after opacification of the right atrium.
Source: ClinicalTrials.gov (NCT04285918). StuddyBuddy aggregates publicly available trial information.